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ABSTRACT
Background To account for differences in body size
in patients with aortic stenosis, aortic valve area (AVA)
is divided by body surface area (BSA) to calculate
indexed AVA (AVAindex). Cut-off values for severe stenosis
are <1.0 cm2 for AVA and <0.6 cm2/m2 for AVAindex.
Objective To investigate the inﬂuence of indexation on
the prevalence of severe aortic stenosis and on the
predictive accuracy regarding clinical outcome.
Methods Echocardiographic and anthropometric data
from a retrospective cohort of 2843 patients with aortic
stenosis ( jet velocity >2.5 m/s) and from 1525 patients
prospectively followed in the simvastatin and ezetimibe
in aortic stenosis (SEAS) trial were analysed.
Results The prevalence of severe stenosis increased
with the AVAindex criterion compared to AVA from 71%
to 80% in the retrospective cohort, and from 29% to
44% in SEAS (both p<0.001). Overall, the predictive
accuracy for aortic valve events was virtually identical
for AVA and AVAindex in the SEAS population (mean
follow-up of 46 months; area under the receiver
operating characteristic curve: 0.67 (95% CI 0.64 to
0.70) vs 0.68 (CI 0.65 to 0.71) (NS). However, 213
patients additionally categorised as severe by AVAindex
experienced signiﬁcantly less valve related events than
those fulﬁlling only the AVA criterion (p<0.001).
Conclusions Indexing AVA by BSA (AVAindex)
signiﬁcantly increases the prevalence of patients with
criteria for severe stenosis by including patients with a
milder degree of the disease without improving the
predictive accuracy for aortic valve related events.
INTRODUCTION
Indexing aortic valve area (AVA) by body surface area
(BSA) (AVAindex) represents an intuitively convincing
and widely adopted method to adjust for differences
in body size.1–3 Whereas current American College
of Cardiology/American Heart Association guidelines
on valvular heart disease recommend indexing AVA
for all patients,2 the recently published European
Society of Cardiology (ESC) guidelines state that
indexing ‘may be helpful, particularly in patients
with an unusually small BSA’.1 In the European
Association of Echocardiography/American Society
of Echocardiography recommendations for clinical
practice, the role of indexing is considered controver-
sial particularly because of the uncertain role of
excess body weight.4
Cut-off values for severe stenosis were set in all
guidelines at <1.0 cm2 for AVA and <0.6 cm2/m2
for AVAindex. However, clinical or outcome studies
supporting this recommendation are rare.5 In
theory, calculation of AVAindex should not change
the overall number of patients with severe stenosis
in a given population but rather result in a decrease
in the percentage of patients with the diagnosis of
severe stenosis in smaller patients and an increase
in larger patients. Based on the hypothesis that
adjusting AVA by BSA, that is, AVAindex, improves
the comparability of stenosis severity in patients
with diverging body size we investigated the impact
of AVAindex on the prevalence of severe aortic sten-
osis and the prediction of clinical events compared
to (unindexed) AVA in two large populations of
patients with aortic valve stenosis and normal left
ventricular function.
PATIENTS AND METHODS
Data from two distinct study populations are pre-
sented. First, we identiﬁed 2843 consecutive
patients investigated at the echocardiographic
laboratory of the Heart Centre Bad Krozingen
between January 1998 and December 2010 dem-
onstrating normal left ventricular function and a jet
velocity of ≥2.5 m/s. Patients with a moderate or
severe mitral or aortic regurgitation, a mean pres-
sure gradient <10 mm Hg or incomplete data were
excluded. Normal left ventricular function was
deﬁned as normal global systolic left ventricular
function with fractional shortening ≥30% without
regional wall motion abnormalities.
The second cohort was recruited from the pro-
spective SEAS study (NCT00092677), which
enrolled 1873 patients with asymptomatic aortic
stenosis, deﬁned by echocardiography at local study
centres as aortic valve thickening and transaortic
Doppler jet velocity ≥2.5 and ≤4.0 m/s. Patients
were randomised from January 2001 to February
2004 to at least 4-year placebo-controlled com-
bined treatment with ezetimibe 10 mg/day and sim-
vastatin 40 mg/day. Patients with coronary heart
disease, heart failure, diabetes, history of stroke or
peripheral vascular disease, clinically signiﬁcant
mitral valve disease, severe or predominant aortic
regurgitation, rheumatic valvular disease, aortic
valve prosthesis or renal insufﬁciency, and patients
already on lipid-lowering therapy or having an indi-
cation for lipid lowering according to guidelines
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were excluded. The original SEAS study showed no difference
in major cardiovascular events between treatment and placebo
group but a signiﬁcant reduction in ischaemic events in patients
treated with ezetimibe/simvastatin.6 The present study popula-
tion comprises 1525 (81.4%) of the 1873 patients recruited in
the SEAS trial with an ejection fraction ≥55% in whom a
detailed echocardiographic assessment by the core laboratory at
baseline was available.
Echocardiography was performed following the guidelines for
the clinical application of echocardiography4 7 8 and has been
described in detail elsewhere.6 9 10 Severe aortic stenosis was
deﬁned according to current guidelines1 2 by an AVA<1.0 cm2
and an AVAindex<0.6 cm
2/m2. The velocity ratio (VR) as a body
size independent measure of aortic stenosis severity was calcu-
lated by the velocity time integral (VTI) of pulsed wave Doppler
in the left ventricular outﬂow tract divided by the VTI of con-
tinuous Doppler through the aortic valve. Anthropometric data
(height and weight) were recorded electronically at the time of
echocardiography. BSA was calculated from the Mosteller
formula11: BSA ¼ ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃðheightweightÞ=3600p . Body mass index
(BMI) was calculated as BMI ¼ weight=height2. The primary
end point of the outcome analysis of the present study was
aortic valve related events (deﬁned as aortic valve replacement,
congestive heart failure due to aortic stenosis, or death from car-
diovascular causes); the secondary end point was cardiovascular
death. All end points had been adjudicated with a predeﬁned
end point protocol by an end point committee blinded for study
conduct and results in the original SEAS study.6 All statistics
were performed using SPSS V.15.0 with continuous variables
presented as mean±SD and categorical variables as percentages.
Percentages were compared with the use of the Pearson χ2 test.
Receiver operating characteristic (ROC) curves were constructed
to assess the sensitivity and speciﬁcity of parameters of AVA and
an AVAindex and to compare their ability to predict aortic valve
events or cardiovascular death. The comparison of areas under
the ROC curves (AUC) was performed as recommended by
DeLong et al.12 The Kaplan–Meier method was used to assess
event-free survival with differences checked by means of the
log-rank test. All testing was two-tailed, and p values of less
than 0.05 were considered to indicate statistical signiﬁcance.
RESULTS
Clinical, anthropometric and echocardiographic data of both
the retrospective cohort from our centre including 2843 patients
and the prospectively followed SEAS population (n=1525) are
summarised in table 1. Whereas the retrospective cohort corre-
sponds to the typically encountered patients with a wide range
of aortic stenosis severity, including very severe stenosis, referred
to a tertiary care centre, the SEAS population represents selected
patients with low cardiovascular risk and predominantly mild to
moderate stenosis.
Prevalence of severe aortic valve stenosis according
to AVA and AVAindex
Indexation by BSA increased the prevalence of severe stenosis in
the retrospective cohort from 71% (AVA<1.0 cm2) to 80%
(AVAindex<0.6 cm/m
2, p<0.001). In the prospective SEAS popu-
lation there was a similar increase from 31% to 44%
(p<0.001). The percentages related to gender are given in
table 2.
To study the impact of indexation on patients with diverging
body size, we stratiﬁed the populations according to BSA quartiles
demonstrating a body size dependency of AVA in both populations
to the effect that larger patients had a lower prevalence of severe
stenosis (ﬁgure 1A,B, p for trend<0.001) whereas AVAindex was
independent of BSA. Compared to AVA, AVAindex did not signiﬁ-
cantly decrease the percentage of patients with severe stenosis in
small patients (BSA ≤1.75 m2: 81% vs 84%, NS, ﬁgure 1A), but
augmented it in the three remaining quartiles in the retrospective
cohort (BSA 1.76–1.88 m2: 81% vs 75%; BSA 1.89–2.03 m2:
77% vs 67%; BSA >2.03 m2: 80% vs 58%, all p<0.001). A
similar pattern was found in the SEAS population (AVAindex vs
AVA: BSA ≤1.76 m2: 43% vs 45%; BSA 1.77–1.89 m2: 43% vs
33%; BSA 1.90–2.03 m2: 44% vs 27%; BSA >2.03 m2: 45% vs
18%, all p<0.001 except AVAindex vs AVA: BSA ≤1.76 m2, NS,
ﬁgure 1B). Calculation of the body size independent VR conﬁrmed
Table 1 Clinical, anthropometric and echocardiographic characteristics
Retrospective cohort (n=2843) SEAS cohort (n=1525)
Mean SD Range Mean SD Range
Age (years) 73.1 10.2 21–97 67.4 9.6 28–85
Female (%) 48 39
Height (cm) 167.4 8.9 140–198 170.5 9.2 145–199
Weight (kg) 77.2 14.9 39–159 78.1 14.2 42–159
Body surface area (m2) 1.89 0.2 1.3–2.8 1.91 0.2 1.4–2.9
Body mass index (kg/m2) 27.5 4.5 15.6–51.9 26.8 4.2 15.5–51.6
LV end-diastolic diameter (mm) 47.4 5.4 28–68 50.2 6.1 26–72
LV end-systolic diameter (mm) 28.5 4.9 11–46 31.6 5.3 16–52
Shortening fraction (%) 40.1 6.5 30–68 37.2 5.9 20–58
Ejection fraction (Teichholz, %) 64.8 7.6 51–91 66.4 7.5 40–88
LVOT diameter (mm) 20.5 2.1 14–31 21.9 2.6 14–32
LVOT flow velocity (m/s) 1.04 0.18 0.7–1.9 0.97 0.20 0.5–1.8
Jet velocity (m/s) 4.1 0.9 2.5–6.7 3.1 0.5 1.7–4.8
Mean pressure gradient (mm Hg) 40.4 17.6 10–117 22.9 8.8 6–64
Aortic valve area (cm2) 0.89 0.32 0.3–2.3 1.28 0.46 0.4–4.0
Aortic valve area index (cm2/m2) 0.47 0.16 0.2–1.1 0.67 0.23 0.2–1.9
Velocity ratio 0.27 0.08 0.1–0.5 0.34 0.10 0.1–0.8
LVOT, left ventricular outflow tract; SEAS, simvastatin and ezetimibe in aortic stenosis trial.6
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comparable stenosis severity between quartiles (mean VR in
the retrospective cohort: BSA≤1.75 m2: 0.26±0.1; BSA
1.76–1.88 m2: 0.26±0.1; BSA 1.89–2.03 m2: 0.27±0.1; BSA
>2.03 m2: 0.27±0.1; mean VR in the SEAS study: BSA≤1.76 m2:
0.33±0.1; BSA 1.77–1.89 m2: 0.33±0.1; BSA 1.90–2.03 m2:
0.34±0.1; BSA>2.03 m2: 0.34±0.1).
Indexation has been recommended speciﬁcally in very small
patients with a BSA<1.5 m2 or a BMI<22.4 5 In our study patients
with a BSA<1.5 m2 were classiﬁed with severe stenosis in 95%
before and 85% after indexation in the retrospective cohort
(n=91, p<0.04) and in 47% vs 37% in SEAS (n=19, p=0.34). In
patients with a BMI<22 indexation had no statistically signiﬁcant
effect on the prevalence of severe stenosis (retrospective cohort
(n=228): 80% vs 77%, p=0.47, SEAS (n=154): 37% vs 40%,
p=0.34). On the other hand and to exclude a potential inﬂuence
of excess body weight,4 we repeated the analysis with the exclusion
of obese patients (BMI ≥30) resulting in a mean BSA of 1.83 m2
and 1.86 m2 for the retrospective and the SEAS cohort, respect-
ively. The pattern of increasing the prevalence of severe aortic sten-
osis in the two cohorts (overall retrospective cohort (n=2128):
AVAindex 78% vs AVA 72%; overall SEAS (n=1227): 42% vs 31%,
both p<0.001) as well as in the predeﬁned BSA quartiles (data not
shown) remained identical. When considering only normal
weighed patients (BMI 18.5–24.9), severe stenosis was diagnosed
according to AVAindex in 42.8% and according to AVA in 34.9% in
the SEAS cohort (p=0.01, n=538). The corresponding values for
the retrospective cohort (n=889) were 76.6% versus 74.4% which
was no longer statistically signiﬁcant (p=0.29).
Inconsistent grading
Indexation has also been recommended speciﬁcally in patients
with ‘inconsistent grading’ (mean pressure gradient ≤40 mmHg,
AVA <1.0 cm2 or, inversely, mean pressure gradient >40 mmHg
and AVA ≥1.0 cm2) in order to reduce discrepancies in the assess-
ment of stenosis severity by gradients and AVA.13 However, based
on the cut-off value for severe stenosis of AVAindex 0.6 cm
2/m2
(and mean pressure gradient 40 mm Hg) the overall number of
‘inconsistently graded’ patients increased rather than decreased
after indexation in both populations (retrospective cohort: from
26% to 32%; SEAS: from 30% to 42%; both p<0.001) and was
unchanged even in the quartile with the smallest patients (retro-
spective cohort: 33% vs 31%; SEAS study 42% vs 41%; both
NS). Adjusting the cut-off to 0.5 cm2/m2 as recently suggested by
Michelena et al14 signiﬁcantly decreased inconsistent grading in
both populations (retrospective cohort: from 32% to 23%; SEAS:
from 42% to 24%, both p<0.001).
Patient outcome according to AVA and AVAindex
In the prospectively followed cohort from SEAS (n=1525) there
were 495 aortic valve events, consisting of 431 aortic valve
Figure 1 Prevalence of severe aortic valve stenosis after stratiﬁcation
according to body surface area (BSA). The prevalence of patients with
severe stenosis according to the aortic valve area (AVA) criterion
(<1.0 cm2) is body size dependent in both the retrospective cohort (a)
and the simvastatin and ezetimibe in aortic stenosis population (b),
with a higher prevalence of severe stenosis in smaller patients.
Calculation of AVAindex decreases body size dependency but increases
the overall prevalence of severe stenosis compared to AVA (p<0.001) in
all quartiles except in small patients (BSA≤1.75/1.76 m2). The
percentage of severe aortic stenosis according to velocity ratio is given
for comparison.
Table 2 Prevalence of severe aortic stenosis according to AVA and AVAindex
AVA<1.0 cm2 AVAindex<0.6 cm2/m2
N % n % p Value
Retrospective cohort (n=2843)
All patients 2011 70.7 2268 79.8 <0.001
Male n=1492 904 60.6 1118 74.9 <0.001
Female n=1351 1107 81.9 1150 85.1 0.03
SEAS cohort (n=1525)
All patients 470 30.8 668 43.8 <0.001
Male n=931 214 23.0 392 42.1 <0.001
Female n=594 256 43.1 276 46.5 n.s.
Prevalence of severe aortic valve stenosis defined by the criterion AVAindex <0.6 cm
2/m2 is increased compared to AVA <1.0 cm2.
AVA, aortic valve area; AVAindex, aortic valve area indexed to body surface area; SEAS, simvastatin and ezetimibe in aortic stenosis trial.
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replacements, 21 heart failures due to progression of aortic sten-
osis and 43 cardiovascular deaths over a mean follow-up of 45.8
±14.1 months. Predictive accuracy for aortic valve events was
unchanged by indexation as quantiﬁed by the AUC (AUC for
AVA: 0.67 (95% CI 0.64 to 0.70); AUC for AVAindex: 0.68 (CI
0.65 to 0.71); NS; ﬁgure 2A). When excluding aortic valve
replacement from the combined endpoint, AVA was superior to
AVAindex in predicting the remaining 64 events of cardiovascular
death and heart failure due to progression of aortic stenosis
(AUC for AVA: 0.61 (CI 0.58 to 0.63) vs AVAindex: 0.58 (CI 0.55
to 0.60), p<0.01). There was no difference in predictive accuracy
with respect to cardiovascular death alone between the two para-
meters of aortic valve stenosis severity (AUC for AVA: 0.61 (CI
0.58 to 0.63); AUC for AVAindex: 0.60 (CI 0.57 to 0.62), NS;
ﬁgure 2B). To further analyse the effect of indexation on rates of
clinical outcome we compared clinical events between the 470
patients with severe stenosis according to AVA with 213 patients
additionally categorised as severe according and limited to the
AVAindex criterion. The latter were more often male, younger and
had a higher BSA (all p<0.001). Over a mean follow-up of
46 months, outcome in the 213 patients was signiﬁcantly better
with respect to aortic valve related events (ﬁgure 3A, p<0.001)
with a trend towards a lower cardiovascular mortality (ﬁgure 3B,
p=0.09), indicating that indexing AVA by BSA and applying a
cut-off value of 0.6 cm2/m2 increases the prevalence of severe
aortic stenosis by including individuals with a milder degree of
the disease.
DISCUSSION
Our data from two large, distinct cohorts totalling 4368 patients
with a wide range of aortic valve stenosis severity indicate that
indexing AVA by BSA (AVAindex) and applying the current parti-
tion value of 0.6 cm2/m2 signiﬁcantly increases the number of
patients with criteria for a severe stenosis by additionally includ-
ing patients with a milder degree of the disease without improv-
ing the predictive accuracy for aortic valve related events and
cardiovascular death.
The percentage of patients with criteria for severe stenosis
may differ depending on the population investigated. We there-
fore studied two distinct cohorts, one drawn from our institu-
tional database representing typical patients referred to a
tertiary care centre with a wide range of aortic stenosis severity
as indicated by a mean jet velocity of 4.1 m/s (range 2.5–6.7).
The other cohort was from the SEAS study comprising a highly
selected population of patients with predominantly mild to
moderate stenosis with a low cardiovascular risk proﬁle as speci-
ﬁed in the exclusion criteria of the trial. Despite the marked dif-
ferences between the two study populations there was an almost
identical pattern with respect to the increases seen in severe
stenosis after calculation of AVAindex.
In theory, calculation of AVAindex should eliminate body size
dependency of AVA and not change the overall number of patients
with severe stenosis in a given population but rather result in a
decrease in the percentage in smaller and an increase in larger
patients. The effect of indexation on the prevalence of severe sten-
osis in the two patient populations investigated in the present
report, however, is quite different from the expected effect.
Although indexation of AVA by BSA (AVAindex) clearly reduced
body size dependency of AVA, using the currently accepted cut-off
value of 0.6 cm2/m2 for AVAindex resulted in an increase of patients
with criteria for severe stenosis over and above that seen with AVA
(cut-off <1.0 cm2) alone. Whereas small patients with a
BSA≤1.75 m2 had no signiﬁcant change in the prevalence of
severe aortic stenosis, AVAindex resulted in an increase in the
remaining patients (covering a BSA between 1.77 and 2.9 m2).
These ﬁndings may in large part be explained by a discrepancy
between partition values. The current relation between AVA and
AVAindex is based on a BSA of 1.67 m
2 (since 1.0/1.67 yields 0.6),
whereas in the current study populations totalling 4368 patients
the mean BSAwas 1.89 and 1.91 m2, respectively.
Special populations
Even in the subgroups of ‘very small’ patients (BSA <1.5 or
BMI<22) there was only a trend towards a reduction of the per-
centage of severe stenosis, a ﬁnding potentially due to small
sample size. Similarly, the increase in patients with severe sten-
osis seen with indexation was markedly more pronounced in
males than in females, possibly due to smaller body size in the
latter. Interestingly, in a recent retrospective Japanese study in
103 comparatively small asymptomatic patients with mean BSA
of 1.5±0.2 m2, an AVAindex of ≥0.6 cm2/m2 was frequently
observed in patients with an AVA<1.0 cm2, 5 and an AVAindex of
<0.6 cm2/m2 was predictive of a poor outcome.
Figure 2 Predictive accuracy of echocardiographic parameters
for valve related events. Receiver operating characteristic (ROC) curves
illustrating the predictive accuracy of aortic valve area (AVA) and body
surface area adjusted AVA (AVAindex) for aortic valve related events
(a) and for cardiovascular death (b) over 46 months of follow-up in
1525 patients with mild to moderate aortic valve stenosis from the
simvastatin and ezetimibe in aortic stenosis study. Area under the ROC
curve was similar between AVA and AVAindex (NS).
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On the other hand, the role of indexation of AVA by BSA in
large patients has been challenged due to overcorrection by the
potential inﬂuence of excess body weight. However, excluding
patients with a BMI≥30 did not change the pattern of increas-
ing the prevalence of severe aortic stenosis in the predeﬁned
BSA quartiles. Therefore, the observed overcorrection in larger
individuals is not a result of obesity.
Indexation has been recommended speciﬁcally in patients with
the clinically challenging constellation of ‘inconsistent grading’ or
‘low gradient severe aortic stenosis’13 in whom AVA indicates
severe stenosis (<1.0 cm2), however, mean pressure gradient
remains below 40 mmHg despite normal ejection fraction and,
therefore, does not fulﬁl the criterion of a severe stenosis. In
theory, indexation should decrease not only the number of patients
with severe stenosis but also the percentage of ‘inconsistent
grading’ in small patients. In contrast, our results demonstrate that
indexation of AVA in fact increases the overall number of patients
with ‘inconsistent grading’ and does not reduce it even in the quar-
tile with the smallest patients. Therefore, rather than improving the
comparability of different parameters for the echocardiographic
assessment of the severity of aortic stenosis, adjustment of AVA by
BSA (AVAindex) with the current cut-off value of <0.6 cm
2/m2 aug-
mented the already existing discrepancies in both populations
investigated. However, adjusting the cut-off for severe stenosis to
AVAindex 0.5 cm
2/m2 as recently suggested,14 substantially
decreased inconsistent grading, supporting the notion that adjust-
ment to the proposed values may be appropriate.
Predictive accuracy for clinical events
In the SEAS population, AVAindex did not improve predictive
accuracy for aortic valve events or cardiovascular death com-
pared to AVA—neither in the whole population nor in patients
with ‘inconsistent grading’ (data not shown)—despite successful
elimination of body size dependency of AVA. Moreover, 213
patients in the SEAS cohort with severe aortic stenosis addition-
ally diagnosed with and limited to the AVAindex criterion had a
better clinical outcome than those with severe stenosis originally
diagnosed with the AVA criterion, indicating that a cut-off value
of 0.6 cm2/m2 for AVAindex increases the prevalence of severe
aortic stenosis by including individuals with a milder degree of
the disease.
Clinical implications
Severe aortic stenosis is currently deﬁned by a peak velocity
>4.0 m/s, mean pressure gradient >40 mm Hg, AVA<1.0 cm2
and AVAindex<0.6 cm
2/m2 in both European1 and North
American guidelines.2 These different measures of stenosis
severity should be interchangeable in the presence of normal
ﬂow conditions. However, recent studies have shown that AVA
tends to overestimate stenosis severity in comparison to peak
velocity and mean pressure gradient.15 16 Furthermore, AVA
introduces a strong correlation to body size, hindering the com-
parability of the different parameters used. The present study
clearly shows that indexation of AVA by BSA reduces body size
dependency of AVA. However, using the current cut-off value
AVAindex<0.6 cm
2/m2 results in a further increase in the number
of patients with severe stenosis over and above that seen with
AVA. Taken together our data demonstrate that the AVAindex cri-
terion of <0.6 cm2/m2 is too high, at least in predominantly
Caucasian populations, and a cut-off <0.5 cm2/m2 may be more
appropriate.14 Importantly and as stated in the current guide-
lines, it should be kept in mind that ‘absolute cut-off points
cannot be relied upon for clinical decision-making and should
be considered in combination with ﬂow rate, pressure gradients,
ventricular function, size and wall thickness, degree of valve cal-
ciﬁcation and blood pressure, as well as functional status’.1
Limitations
There are some limitations with this analysis. First, the calculations
were performed on data from two mostly northern and western
European patient populations and may not apply to populations
with signiﬁcantly different anthropometric characteristics.5
Second, alternative formulae for the assessment of BSA exist,
Figure 3 Outcome in patients additionally diagnosed with severe
aortic stenosis (AS) due to the aortic valve area (AVA) index (AVAindex)
criterion. Kaplan–Meier plots illustrating signiﬁcantly less aortic valve
events in 213 patients additionally categorised as severe according
and limited to the AVAindex criterion (<0.6 cm
2/m2) compared to
470 patients with severe stenosis according to AVA (<1.0 cm2,
p<0.001) (a); together with a trend towards lower cardiovascular
mortality (p=0.09) (b).
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however calculation of BSA based on work by Dubois and
Dubois17 did not change results signiﬁcantly (data not shown).
Third, the validity of linear adjustment of cardiac dimensions by
BSA has been questioned18 and stratiﬁcation of patients according
to quartiles of BSA may therefore be an oversimpliﬁcation with
respect to the relationship between AVA and body size. Forth, over-
weight status may be a limitation of AVAindex,
14 since BSA corrects
not only for individual body size but also for acquired fat tissue.
The adequate method to correct for excess body weight has not
been clariﬁed yet, but obesity could have contributed to the
increased prevalence of severe aortic stenosis in large individuals.
However, restricting the analysis to normal weight patients
retained the pattern of increasing prevalence of severe aortic sten-
osis by AVAindex compared to AVA.
CONCLUSION
Indexing AVA by BSA and applying the current partition value
of AVAindex <0.6 cm
2/m2 for severe stenosis increases the preva-
lence of severe aortic valve stenosis compared to unindexed AVA
by including individuals with a milder degree of disease without
improving the predictive accuracy for clinical events.
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